Kyoritsu Seiyaku

What Kyoritsu Seiyaku does

Kyoritsu Seiyaku Corporation (共立製薬株式会社), founded in 1955 and headquartered in Chiyoda-ku, Tokyo, is a private Japanese animal health company operating within the Kyoritsu Holdings Group. The company develops, manufactures, and distributes veterinary pharmaceuticals, vaccines, biologics (including monoclonal antibodies in development), and chemical deodorizers across three primary segments: companion animals (dogs and cats), livestock (cattle, pigs, poultry), and aquaculture (notably yellowtail fish). Its product portfolio includes proprietary brands such as Epoleon (chemical reaction-type deodorizer), Checkman NT-proANP (world's first canine cardiac screening kit, launched March 2025), Piscivac Rensa Alpha 3 oil (world's first 3-valent yellowtail vaccine, launched May 2025), Startvac (Japan's only approved bovine mastitis vaccine), and Fiprospot Plus parasiticides. Manufacturing is conducted at GMP-certified facilities in Saitama, Hiroshima, and Tsukuba (with a new 5,319 sqm R&D building operational from February 2026).

The company operates a vertically integrated go-to-market combining direct enterprise field sales through 15 regional offices across Japan, business-to-business sales to animal hospitals via the Kakaritsuke Animal Hospital Registration System (112,000 registered users within 5 months of launch), and direct-to-consumer channels including the KS Online e-commerce store, KS Pet Health Link platform, and the Official LINE service (launched September 2025). Revenue is generated primarily through one-time product sales of pharmaceuticals and vaccines to animal hospitals, livestock farms, and aquaculture producers, with selective subscription/recurring revenue from Royal Canin therapeutic diet distribution and pet supplements.

Internationally, Kyoritsu Seiyaku operates a 100% UK subsidiary (Carus Animal Health Limited, established 2017), a joint venture in China with Jinyu Baoling Biologics (Jinyu Kyoritsu Animal Health, established November 2019), and has made strategic biotech investments including a ¥4.05 billion Series B investment in PetMedix Ltd (2021) for companion animal antibody development. Active R&D partnerships include bitBiome (bio-manufacturing, announced March 2026), MabGenesis (canine monoclonal antibodies), Tohoku University (animal mucosal immunology, 2023-2026), and IBM Japan (VRAINERS platform). The company employs 501-1,000 people and is led by President Takaaki Takai.

Name

Kyoritsu Seiyaku

Legal name

共立製薬株式会社

Website

https://kyoritsuseiyaku.co.jp

Company type

Private

Founded year

1955

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Kyoritsu Seiyaku is a 70-year-old Japanese animal health company that develops, manufactures, and distributes veterinary pharmaceuticals, vaccines, biologics, and chemical deodorizers for companion animals, livestock, and aquaculture through a vertically integrated network of manufacturing facilities and 15 domestic sales offices.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Veterinary Services (54194), Veterinary Services (541940)

SIC

Biological Products, (No Disgnostic Substances) (2836), Agricultural Prod-Livestock & Animal Specialties (200)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK), Pharmacy, Biologics & Veterinary Supply Dispensing (Farm Animal) (AFACADAM), Veterinary Vaccine & Biologics Distributors (HLAMAIAC), Veterinary Vaccines (HLAIAEAH), Multi-site/Corporate Group Operations Platforms (Franchise/MSO Tools, Standardization) (HLAMAGAM)

Keywords

• Veterinary pharmaceuticals
• Animal vaccines
• Livestock aquaculture health
• Companion animal medicine
• Veterinary diagnostic kits

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices17 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Veterinary Pharmaceuticals Sales: Sale of veterinary pharmaceuticals including vaccines, antimicrobial agents, parasiticides, and monoclonal antibody drugs for companion animals (dogs/cats) and livestock/aquaculture species.
2. Epoleon Deodorizer Products: Sale of chemical reaction-type deodorizers for livestock farms, composting facilities, factories, waste treatment facilities, and other industrial applications.
3. Pet Owner Products and Services: Online sales of pet supplements (KS Online), therapeutic diet distribution through registered hospital network, calendar products, and pet owner engagement platforms.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

Kyoritsu Seiyaku develops, manufactures, and sells veterinary pharmaceuticals, vaccines (including biologics and monoclonal antibodies), and diagnostic products for companion animals (dogs and cats) and livestock/aquaculture species. The company also operates digital platforms linking veterinarians, pet owners, and livestock farmers, and distributes Epoleon chemical-reaction deodorizers for livestock facilities, factories, and waste treatment operations.

Product overview

Kyoritsu Seiyaku is a Japanese animal health company operating as part of Kyoritsu Holdings Group. The company offers a diversified portfolio of veterinary pharmaceuticals, vaccines, diagnostic products, and digital platforms for companion animals (dogs, cats), livestock (cattle, pigs, chickens), and aquaculture (yellowtail fish). The product portfolio includes: (1) Core veterinary pharmaceuticals including antibacterial agents like Enrofloxacin and parasiticides like Fiprospot Plus; (2) Vaccines including Startback (bovine mastitis vaccine), Piscivac Rensa Alpha 3 oil (fish vaccine); (3) Diagnostic products including Checkman NT-proANP (canine heart disease screening kit); (4) Epoleon chemical reaction-type deodorants for livestock facilities; (5) Digital platforms including AI Dr. Holmes (AI-powered pet health consultation), VRAINERS (animal hospital medical platform), KS Online (pet supplement e-commerce), Veterinary Adoption (pet adoption matching), Chikusan Navi (livestock industry web media), and Designated Animal Hospital Registration Site (Royal Canin therapeutic food distribution platform). The company also produces and sells consumer products including Royal Canin therapeutic foods and daily calendars.

Differentiator

Problem solved

Functional benefit

Brands

• Epoleon (エポリオン): Chemical reaction-type deodorant products for livestock farms, factories, and various industrial applications. Uses betaine compounds and plant-derived fragrances to neutralize odors.
• Checkman NT-proANP
• Startvac (スタートバック)
• Pisciback (ピシバック)
• Veterinary Adoption
• Chikusan Navi (畜産ナビ)

Products and services

• Veterinary Pharmaceuticals and Vaccines Broad portfolio of veterinary pharmaceuticals and vaccines for companion animals and livestock/aquaculture species, including antibacterial agents, parasiticides, vaccines, and therapeutic products. Sold primarily to veterinary hospitals, livestock farmers, and aquaculture producers.
• Epoleon (エポリオン) Deodorant Chemical reaction-type deodorant using betaine compounds to neutralize acidic odors (hydrogen sulfide, methyl mercaptan) and alkaline odors (ammonia, trimethylamine), as well as rancid odors. Sold to livestock farms, composting facilities, factories, and waste treatment facilities.
• Checkman NT-proANP World's first in-clinic cardiac disease screening test kit for dogs that measures NT-proANP biomarker reflecting atrial load in approximately 20 minutes using a small amount of plasma, without specialized equipment. Particularly suitable for mitral valve insufficiency common in dogs. Approved veterinary in-vitro diagnostic with patents in Japan and China.
• Startback (スタートバック) Mastitis Vaccine Japan's first and only approved mastitis vaccine for cattle. Targets Staphylococcus aureus which causes mastitis and forms biofilms. Produces antibodies against slime (biofilm components) secreted by S. aureus to reduce mastitis symptoms. Sold to dairy farmers and veterinarians.
• Piscivac Rensa Alpha 3 Oil (ピシバック注 レンサα3 oil) World's first 3-valent combination vaccine preventing all three serotypes (I, II, III) of alpha-hemolytic streptococcal disease in yellowtail fish (Seriola species). Oil adjuvant vaccine offering longer immune persistence than aqueous vaccines. Approved for Kampachi (yellowtail). Sold to aquaculture producers.
• Enrofloxacin Injection 100 KS (エンロフロキサシン注100「KS」) Fluoroquinolone antibacterial agent for livestock. Originally approved for cattle pneumonia and E. coli diarrhea; acute and severe acute mastitis added in February 2022. Effective against gram-negative bacteria such as Klebsiella causing mastitis. DNA replication inhibition effect. Sold to veterinarians and livestock farmers.
• Fiprospot Plus Dog/Cat (フィプロスポットプラス) Niche, tick, louse, and biting lice extermination products for dogs and cats. Round-tipped pipette tube design prevents skin contact for safe application. Domestically manufactured in five sizes with color-coded packaging. Sold to veterinary hospitals and pet owners.
• AI Dr. Holmes (AI Dr.ホームズ) AI-powered chat-based health consultation service for pet owners. Allows pet owners to ask health-related questions about their pets via a chat interface using natural language processing.
• KS Online Online store selling high-quality dog and cat supplements and care products directly to pet owners. Operated by Kyoritsu Seiyaku at ks-online.jp.
• VRAINERS (ブレイナーズ) Animal medical platform developed jointly with IBM Japan. Provides electronic medical record systems for animal hospitals and coordination apps connecting pet owners with animal hospitals.
• Designated Animal Hospital Registration Site (かかりつけ動物病院登録サイト) Registration platform enabling pet owners to register their designated animal hospital for purchasing Royal Canin therapeutic foods under veterinary guidance. Reached 112,000 registered users within 5 months of launch.
• Veterinary Adoption Shelter dog and cat adoption matching platform connecting partner animal hospitals with prospective adopters. Achieved over 820 successful adoptions by June 2015.
• Himeduri Wanko / Hinomaru Nyaneko Calendar (日めくりワンコ/日めくりニャンコ) Daily tear-off calendars featuring photos of dogs (Himeduri Wanko) and cats (Hinomar Nyaneko) submitted by pet owners nationwide. Sold at 2,178 yen (tax included) at animal hospitals, bookstores, and online.

Quantifiable outcome

• World's first 3-valent vaccine preventing all serotypes (I, II, III) of alpha-hemolytic streptococcal disease in yellowtail fish
• +1 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core.

• bitBiome, Inc.coreStrategic or Co-development Partner · 9 March 2026Strategic collaboration to develop biotechnological products for animal health and nutrition. bitBiome contributes its bio-manufacturing technology platform integrating the world's largest microbial sequence database, enzyme engineering, and genome modification technology. Kyoritsu Seiyaku contributes decades of veterinary expertise for pets and livestock. Partnership aims to commercialize developed technologies globally and address global animal health and sustainability challenges.
• 株式会社津田 (Tsuda Corporation)coreStrategic or Co-development Partner · 20 January 2026Co-development partner for classical swine fever oral vaccine for wild boars. Tsuda manufactures bait materials with boar attractant fragrances integrated into biodegradable materials containing vaccine packets.
• 塩野香料株式会社 (Shiono Goods Co., Ltd.)coreTechnology or Integration · 20 January 2026Development and provision of boar attractant fragrances for classical swine fever oral vaccine bait. Leverages expertise in fragrance development for social problem solutions.
• Toyota Woven City (トヨタ自動車株式会社 / ウーブン・バイ・トヨタ株式会社)coreStrategic or Co-development Partner · 4 August 2025Participation as 'Inventor' in Toyota Woven City smart city initiative. Aims to develop urban guidelines and mobility infrastructure for pet-human coexistence through various demonstration experiments. Official launch event participation September 2025.
• MabGenesis株式会社coreStrategic or Co-development Partner · 7 June 2023Joint research contract for canine monoclonal antibody drugs. Combining MabGenesis's canine MOURA library and IMPACT antibody acquisition technology with Kyoritsu's development capabilities and industry leadership to create innovative animal antibody drugs for Japan and global markets.
• 東北大学耳鼻咽喉学研究科 (Tohoku University Graduate School of Agricultural Science)coreStrategic or Co-development Partner · 3 April 2023Established 'Animal Mucosal Immunology Joint Research Department' (April 2023-March 2026). Research goal: develop materials (microorganisms, metabolites) for mucosal infectious disease control without relying solely on antimicrobial substances. Initial focus: useful microorganism transplantation for calf diarrhea treatment.
• 金宇保霊生物用品有限公司 (Jinyu Baoling Biologics Co., Ltd.)coreStrategic or Co-development Partner · 6 November 2019Joint venture 金宇共立動物保健有限公司 established with China's largest animal vaccine manufacturer Jinyu Baoling (subsidiary of Jinyu Bio-tech).
• 日本アイ・ビー・エム株式会社 (IBM Japan)coreTechnology or Integration · 27 November 2018Co-development of animal medical platform VRAINERS™ (trademark pending) providing electronic medical records and coordination apps for animal hospitals. Service launched October 2019.
• Carus Animal Health LimitedcoreOthers · 1 June 2017100% owned UK subsidiary established to explore innovative European technologies and bring them to market.

Scale indicators6 records

Recent moves9 records

Expansion highlights8 records

Direct peers

• Phibro Animal Health: Global animal health and nutrition company specializing in livestock vaccines, antibacterials, parasiticides, and feed additives. Direct comparator in livestock/animal nutrition category where Kyoritsu competes with vaccines, antimicrobials, and mineral nutrition.
• Vetoquinol: Mid-sized European animal health company focused on companion animal therapeutics and livestock pharmaceuticals. Comparable in size and category breadth to Kyoritsu, both specializing in veterinary pharmaceuticals with established European-Asian distribution.
• IDEXX Laboratories: Global leader in veterinary diagnostics including in-clinic analyzers and reference lab services. Directly comparable to Kyoritsu's Checkman NT-proANP point-of-care diagnostic kit, with broader scale and established veterinary hospital relationships.
• DS Pharma Animal Health: Japanese animal health subsidiary of Sumitomo Dainippon Pharma (now Sumitomo Pharma) developing veterinary pharmaceuticals including companion animal and livestock products. Direct head-to-head competitor to Kyoritsu in Japan across small animal pharmaceuticals and livestock vaccines.
• Virbac: Independent global animal health company specializing in companion animal pharmaceuticals, vaccines, and parasiticides. Comparable to Kyoritsu in offering niche veterinary biologics and specialty therapeutics with strong veterinary channel relationships in multiple geographies.
• Nippon Zenyaku Kogyo (ZENOAQ): Japan's leading domestic veterinary pharmaceutical manufacturer focusing on companion animal biologics, vaccines, and pharmaceuticals. Most direct Japanese comparable to Kyoritsu with similar product mix across dogs, cats, and livestock, and overlapping distribution into Japanese animal hospitals.

Broad incumbents

• Elanco Animal Health: Major global animal health competitor offering companion animal pharmaceuticals (parasiticides, dermatology) and livestock vaccines/antibiotics. Direct competitor in companion animal parasiticides (Fiprospot Plus competes with Elanco's parasiticides) and livestock vaccines.
• Zoetis: The world's largest pure-play animal health company, offering vaccines, pharmaceuticals, diagnostics, and diagnostics across companion and livestock animals. Direct competitor across Kyoritsu's core categories of veterinary biologics, parasiticides, and companion animal pharmaceuticals, but at much larger global scale.
• Boehringer Ingelheim Animal Health: Second-largest global animal health company with strong veterinary vaccines, parasiticides, and therapeutics franchises. Competes with Kyoritsu globally in livestock vaccines and companion animal monoclonal antibodies/biologics, including cardiovascular and immunology indications.

Regional players

• Jinyu Baoling Biologics: China's largest veterinary vaccine manufacturer and Kyoritsu's joint venture partner in Jinyu Kyoritsu Animal Health (2019). Regional peer that primarily serves the Chinese livestock vaccine market and provides Kyoritsu with China market access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kyoritsu Seiyaku